SCHEMBL1604499

SCHEMBL1604499

C[CH]C1CCCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27775118 1.00
SCHEMBL27795996 1.00
SCHEMBL1515328 0.92
SCHEMBL29261958 0.85
SCHEMBL3604014 0.79
SCHEMBL16556581 0.79
SCHEMBL3602468 0.79
SCHEMBL3602463 0.79
SCHEMBL12456107 0.79
Hydrochloric Acid SCHEMBL3594515 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2968338-A2 NOVEL USES Intra-Cellular Therapies, Inc. (US) 2016-01-20 EP claimed
EP-2956141-A1 NOVEL USES Intra-Cellular Therapies, Inc. (US) 2015-12-23 EP claimed
WO-2014145617-A2 NOVEL USES INTRA-CELLULAR THERAPIES, INC. (US) 2014-09-18 WO claimed
WO-2014127331-A1 NOVEL USES INTRA-CELLULAR THERAPIES, INC. (US) 2014-08-21 WO claimed
US-20130296228-A1 EFFLUX PUMP INHIBITORS PATEL MAHESH VITHALBHAI (IN) 2013-11-07 US claimed
EP-2590657-A1 ORGANIC COMPOUNDS Intra-Cellular Therapies, Inc. (US) 2013-05-15 EP claimed
EP-2575817-A1 ORGANIC COMPOUNDS Intra-Cellular Therapies, Inc. (US) 2013-04-10 EP claimed
US-20130059774-A1 EFFLUX PUMP INHIBITORS PATEL MAHESH VITHALBHAI (IN) 2013-03-07 US claimed
EP-2536408-A1 EFFLUX PUMP INHIBITORS Wockhardt Research Centre (IN) 2012-12-26 EP claimed
WO-2011153136-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. (US) 2011-12-08 WO claimed
EP-1636214-A1 BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF Astrazeneca AB (SE) 2006-03-22 EP claimed
EP-1636194-A1 BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF AstraZeneca AB (SE) 2006-03-22 EP claimed
WO-2005021533-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2005-03-10 WO claimed
WO-2005021532-A1 SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2005-03-10 WO claimed
WO-2004108712-A1 BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF ASTRAZENECA AB (SE) 2004-12-16 WO claimed
WO-2004108688-A1 BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF ASTRAZENECA AB (SE) 2004-12-16 WO claimed
WO-2004108689-A1 BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF ASTRAZENECA AB (SE) 2004-12-16 WO claimed
WO-2004085425-A1 FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS AMGEN INC (US) 2004-10-07 WO claimed
EP-1218353-A1 QUINAZOLINE DERIVATIVES AstraZeneca UK Limited (GB) 2002-07-03 EP claimed
WO-2001004102-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA UK LIMITED (GB) 2001-01-18 WO claimed